Do Dietary Factors Influence Risk of Developing MPNs?
An analysis of data from the NIH-AARP Diet and Health Study evaluated the association between consumption of various foods and the development of MPN.
Myeloproliferative Neoplasms
Integrative Medicine Therapies Effectively Increase Quality of Life for Patients With Myeloproliferative Neoplasms
An evaluation of more than 2 dozen types of integrative medicine therapies demonstrated that patients with MPNs who engaged in these activities had improved negative symptoms and quality of life.
Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Neoplasms
A new meta-analysis indicates that the true prevalence of pulmonary hypertension linked to myeloproliferative neoplasms is not well understood.
Promising Early Results for Ruxolitinib-Decitabine Combination in MPN in Accelerated and Blast Phases
A small, single-arm, phase 2 study results demonstrate efficacy and safety of this combination therapy in patients with MPN-AP or MPN-BP.
Polycythemia Vera and Essential Thrombocythemia: Diagnosis, Risk-Stratification, Management Updates
Investigators summarized current literature surrounding the diagnosis and risk-stratification of PV and ET, and reviewed available and upcoming therapies.
Assessment and Management of Patients with Polycythemia Vera
Some pointers from a review of assessment and management strategies for nurses caring for patients with polycythemia vera.
Depression Common Among Patients With a Myeloproliferative Neoplasm
Using validated tools, investigators determined that patients with a MPN were likely to experience significant symptoms of depression.
Some Patients With AML Secondary to MPN May Benefit From Venetoclax in Combination With a Hypomethylating Agent
Venetoclax, a BCL2 inhibitor, used in combination with a HMA improved outcomes in a cohort of 9 patients with AML secondary to MPN.
Interferon Alpha and Pegylated Interferon Alpha Can Be Safe, Effective for Treatment of Essential Thrombocythemia and Polycythemia Vera
Interferon-alpha and pegylated interferon-alpha, as well as hydroxyurea and anagrelide, represent cytoreductive approaches to the treatment of patients with ET and PV.
Germline Factors Affect Molecular Response to Treatment for Polycythemia Vera
Germline polymorphisms can affect response to treatment in people with polycythemia vera.
-
Loading...
-
Loading...
Next post in General Hematology
